Materialise and Tissue Regeneration Systems Announce Partnership

Materialise (NASDAQ:MTLS) and Tissue Regeneration Systems (TRS) have announced a partnership to produce 3D-printed tracheal splints. These will be used in clinical trials.
According to the press release:

Materialise’s Mimics Innovation Suite was used to design the splint which is constructed from a bioresorbable technology platform licensed to TRS by the University of Michigan in 2007. After several years refining fabrication methods, TRS received its first commercial product clearance from the FDA in 2013. The Materialise partnership is one of several co-development projects currently underway at TRS.
Thanks to FDA approval for Expanded Access to an investigational medical device, the splints are used to treat tracheobronchomalacia (TBM), a condition affecting 1 in 2,220 babies which can cause the airway to spontaneously collapse.

Click here to read the full press release.